LeAnn Mendoza, None;
Mark Christopher, None;
Akram Belghith, None;
Christopher Bowd, None;
Jasmin Rezapour, None;
Massimo Fazio, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindness (F);
Michael Goldbaum, None;
Robert Weinreb, Aerie Pharmaceuticals (C), Allergan (C), Bausch&Lomb (C), Bausch&Lomb (F), Carl Zeiss Meditec (F), Centervue (F), Eyenovia (C), Heidelberg Engineering (F), Konan Medical (F), Meditec-Zeiss (P), Optovue (F), Toromedes (P);
Christopher Girkin, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindness (F);
Jeffrey Liebmann, Aerie (C), Alcon (C), Allergan (C), Bausch & Lomb (C), Bausch & Lomb (F), Carl Zeiss Meditec (F), Carl Zeiss Meditech (C), Eyenova (C), Galimedex (C), GmbH (C), Heidelberg Engineering (C), Heidelberg Engineering (F), National Eye Institute (F), Novartis (C), Optovue (F), Reichert (C), Reichert (F), Research to Prevent Blindness (F), Topcon (F), Valeant Pharmaceuticals (C);
C Gustavo De Moraes, Belite (C), Carl Zeiss (C), Galimedix (C), Heidelberg Engineering (R), Novartis (C), Perfuse Therapeutics (C), Reichert (C), Topcon (R);
Linda Zangwill, Carl Zeiss Meditec (F), GmbH (F), Heidelberg Engineering (F), Heidelberg Engineering (R), Meditec-Zeiss (P), National Eye Institute (F), Optovue (F), Topcon Medical Systems (F)